Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer, according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology Annual Meeting.
Nearly all women who have been treated for non-metastatic breast cancer suffer from health problems after primary treatment.
Nearly ninety per cent of all cancer patient deaths are due to metastasis. A study from Uppsala University shows that a process that allows the cells to metastasize is aided by the synthesis of new ribosomes, the cell components in which proteins are produced.
Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer.
The American Society for Radiation Oncology and the American Urological Association today announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of prostate cancer recurrence to include new published research related to adjuvant radiotherapy.
A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer Research UK.
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
Two years after diagnosis, breast cancer survivors have four times more positive than negative thoughts about changes they experienced because of their illness, a new study found.
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.
Atypical ductal hyperplasia is a breast lesion associated with a four- to five-fold increase in the risk of breast cancer.
Some types of cancer cannot be treated with classical chemotherapy. Scientists from Inserm, CNRS, Sorbonne University, PSL university, University Grenoble Alpes and ESRF, the European Synchrotron, are working on a metallorganic molecule as an antitumor drug.
Risk factors for stroke rise sharply in post-menopausal women in the first year after they are diagnosed with breast cancer, according to preliminary research to be presented in Honolulu at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
TherapeuticsMD, Inc., an innovative women's healthcare company, today announced that the United States Food and Drug Administration has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
Biomarkers can predict whether women will respond to the first-line treatment for endometriosis, an extremely painful condition in which the tissue usually found inside the uterus grows in places it shouldn't, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.
There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.
Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.
Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.
A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.